Skip to main content
SpringerLink
Log in

HER2-targeted antibody-drug conjugates: no increase in risk of fatal AEs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials BMC Cancer : 10 Oct 2023. Available from: URL: https://doi.org/10.1186/s12885-023-11250-1

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

HER2-targeted antibody-drug conjugates: no increase in risk of fatal AEs. Reactions Weekly 1979, 7 (2023). https://doi.org/10.1007/s40278-023-47734-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-47734-x

Search

Navigation